FDAnews
www.fdanews.com/articles/209939-angle-presents-positive-data-on-its-cancer-analysis-system

Angle Presents Positive Data on Its Cancer Analysis System

October 26, 2022

UK-based liquid biopsy company Angle said its Parsortix system delivered promising results in a proof of concept study that demonstrated that removal of plasma from a blood sample did not affect the quality of the sample.

The Parsortix system received FDA’s De Novo clearance earlier this year for use in analysis of blood samples from metastatic breast cancer patients. The company said the study showed that it is possible to isolate both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from a single blood sample while maintaining the plasma for subsequent ctDNA analysis from a single tube of blood with minimal additional handling.

Isolating both CTC and ctDNA “can provide complementary information valuable for prognostic, therapy selection and patient monitoring,” the company said.

Angle presented the study results at the International Society of Liquid Biopsy meeting in Miami, Fla., Oct. 20-22.

View today's stories